Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Now Viewing

EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!